These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28295180)

  • 1. 24-h continuous infusion of platelets for patients with platelet transfusion refractoriness.
    Cid J; Guijarro F; Carbassé G; Lozano M
    Br J Haematol; 2018 May; 181(3):386-389. PubMed ID: 28295180
    [No Abstract]   [Full Text] [Related]  

  • 2. Dengue hemorrhagic fever in Trinidad and Tobago: a case for a conservative approach to platelet transfusion.
    Sharma A; Charles K; Chadee D; Teelucksingh S
    Am J Trop Med Hyg; 2012 Mar; 86(3):531-5. PubMed ID: 22403331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
    Vo P; Purev E; West KA; McDuffee E; Worthy T; Cook L; Hawks G; Wells B; Shalabi R; Flegel WA; Adams SD; Reger R; Aue G; Tian X; Childs R
    Br J Haematol; 2020 May; 189(3):551-558. PubMed ID: 32086819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet transfusion refractoriness and anti-HLA immunization.
    Blandin L; Dougé A; Fayard A; Bay JO; Berlie G; Pereira B; Lemal R; Rouzaire P
    Transfusion; 2021 Jun; 61(6):1700-1704. PubMed ID: 33709433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet transfusion for patients with cancer.
    Fletcher CH; DomBourian MG; Millward PA
    Cancer Control; 2015 Jan; 22(1):47-51. PubMed ID: 25504278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet transfusion: Alloimmunization and refractoriness.
    Prodger CF; Rampotas A; Estcourt LJ; Stanworth SJ; Murphy MF
    Semin Hematol; 2020 Apr; 57(2):92-99. PubMed ID: 32892848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended platelet transfusion in bleeding patients with platelet transfusion refractoriness.
    Fernández-Barge T; Domínguez-García JJ; Díaz-Santander A; Rivero-Fernández R; Cantera-Estefanía R; Mendez GA; Romón Í
    Transfus Apher Sci; 2023 Aug; 62(4):103711. PubMed ID: 37059653
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
    Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D
    Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractoriness to platelet transfusion.
    Rebulla P
    Curr Opin Hematol; 2002 Nov; 9(6):516-20. PubMed ID: 12394175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
    Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
    Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions.
    Lee RH; Kasthuri RS; Bergmeier W
    Curr Opin Hematol; 2020 Nov; 27(6):378-385. PubMed ID: 32868672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-unit compared to two-unit platelet transfusions for adult oncology outpatients.
    Gehrie EA; Frank SM; Visagie M; Grabowski MK; Tobian AAR; Strockbine VL; DeMario VM; Lawrence CE; Hambley BC; Uglik K; Ness PM; DeZern AE; Bloch EM
    Vox Sang; 2019 Jul; 114(5):517-522. PubMed ID: 31056742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. It's About Time: Transfusion effects on postinjury platelet aggregation over time.
    Kornblith LZ; Decker A; Conroy AS; Hendrickson CM; Fields AT; Robles AJ; Callcut RA; Cohen MJ
    J Trauma Acute Care Surg; 2019 Nov; 87(5):1042-1051. PubMed ID: 31389915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of antiplatelet therapy in traumatic intracranial hemorrhage: Does timing matter?
    Pandya U; Malik A; Messina M; Albeiruti AR; Spalding C
    J Clin Neurosci; 2018 Apr; 50():88-92. PubMed ID: 29452965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia.
    Salama A; Kiesewetter H; Kalus U; Movassaghi K; Meyer O
    Thromb Haemost; 2008 Nov; 100(5):762-5. PubMed ID: 18989518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal and pediatric platelet transfusions: current concepts and controversies.
    Patel RM; Josephson C
    Curr Opin Hematol; 2019 Nov; 26(6):466-472. PubMed ID: 31503020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status of Platelet Transfusion in Pediatric Patients.
    Sloan SR; Parker RI
    Transfus Med Rev; 2016 Oct; 30(4):230-4. PubMed ID: 27559006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.